Quick Summary:
PRP uses a patient’s own processed blood platelets and has a larger human clinical evidence base for selected hair-loss conditions, but preparation methods, schedules and outcomes remain inconsistent. Exosome products are externally prepared biological products or derivatives marketed under a broad label; current hair-loss evidence is earlier and less standardised, with important manufacturing, contamination, dosing, regulatory and long-term-safety questions. Neither treatment diagnoses the cause of loss, creates unlimited follicles or guarantees regrowth. Diagnosis and conventional options should be discussed before an injectable package.
PRP and exosome products differ in source, standardisation and evidence maturity; neither label replaces diagnosis, product disclosure or informed consent.
PRP and exosome treatments are often placed beside each other on a clinic menu as if they were two strengths of the same injection. They are not. PRP is prepared from the patient’s own blood, with the aim of concentrating platelets and related signalling molecules. “Exosome” can refer to externally manufactured products with different sources, purification, contents and quality controls.
The evidence and uncertainty are therefore different. Before comparing sessions or prices, the patient needs a hair-loss diagnosis and a clear answer to a more basic question: what exactly will be injected?
Neither injection replaces diagnosis
Pattern hair loss may respond differently from alopecia areata, scarring alopecia, traction, postpartum shedding, thyroid-related change, nutritional deficiency or scalp infection. Active inflammation can destroy follicles and may require specialist medical treatment. An injectable package cannot safely group these conditions under “weak roots.”
History should include timing, pattern, family history, scalp symptoms, health, medicines, pregnancy, diet and previous treatment. Examination may include magnification and a hair-pull assessment; targeted tests or dermatology input may be appropriate. If the cause is uncertain, treatment should pause rather than use response to an injection as a diagnostic test.
What PRP is—and why protocols vary
Platelet-rich plasma is made by drawing blood and using centrifugation or another system to separate a platelet-containing fraction. The final platelet concentration, white-cell content, activation, volume and injection depth vary between systems. “PRP” is not one standard product even though it is autologous.
Systematic reviews report potential improvement in selected alopecia outcomes, but studies use different preparation, schedules, comparators and measurements. This means PRP can be discussed as an option with a larger human evidence base than exosome products while still avoiding a guaranteed density, fixed schedule or claim that every protocol is equivalent.
What an exosome product may be
Exosomes are small extracellular vesicles involved in cell communication. Commercial products marketed for hair loss may be derived from different cell sources or manufacturing processes, and some may use the term loosely. Contents, purity, potency, sterility, storage and batch consistency cannot be inferred from the label alone.
Early laboratory and small clinical studies are scientifically interesting, but current reviews identify important gaps in standardisation, regulation, long-term safety and high-quality comparative evidence. A biological mechanism or before-and-after series does not prove durable patient benefit. Unknowns should be visible in consent, not presented as proof of innovation.
Evidence and practical differences
| Question | PRP | Exosome-labelled product |
|---|---|---|
| Source | Patient’s own processed blood | Externally manufactured biological material; source varies |
| Standardisation | Protocols remain heterogeneous | Product and manufacturing variability is a major issue |
| Clinical evidence | Larger human literature, with inconsistent methods and outcomes | Earlier and smaller evidence base; long-term gaps |
| Key product question | How was blood processed and what was injected? | Exact manufacturer, source, batch, sterility and contents |
| Regulation | Procedure and device context varies | Must be checked for the exact product and country |
| Promise to avoid | Guaranteed regrowth | Regeneration or superiority claims |
Regulatory language must be country-specific
The US Food and Drug Administration states that there are no FDA-approved exosome products. That is relevant when a clinic cites “FDA approval,” but it does not automatically determine whether a product is lawfully registered or supplied in Pakistan. Pakistani status must be checked through the appropriate local product and clinical-regulatory pathway.
Ask for the exact product—not a photograph of a generic vial—and request manufacturer, source material, batch number, storage, sterility testing, indication and current local status. “Imported,” “medical grade” and “Korean” are not regulatory categories or evidence of effectiveness.
Who may reasonably discuss PRP?
A patient with a defined non-scarring hair-loss condition, viable miniaturising follicles and realistic expectations may discuss PRP as one part of a plan. It cannot create new donor supply in a smooth bald area and does not replace transplantation when follicle redistribution is the agreed goal.
Blood disorders, platelet problems, infection, anticoagulant use, pregnancy and other health factors require individual assessment. Suitability for a blood draw is not the same as proof of benefit. A stop rule should be agreed so a patient does not continue an expensive series without measurable change.
Why exosome candidacy needs a higher evidence threshold
Because products and supporting evidence vary, “candidate” is not defined by hair loss alone. The clinician must establish lawful, traceable product use, credible human evidence for the indication, sterile handling, known and unknown risks and a response plan. If those details cannot be supplied, informed consent is incomplete.
A patient should not be told that exosomes are simply stronger PRP or a replacement for a transplant. Combining both also does not prove added benefit. Every additional injection and product adds cost and potential harm and needs its own rationale.
Risks, discomfort and warning signs
Scalp injections can cause pain, bleeding, bruising, headache, swelling, vasovagal symptoms, inflammation, infection and temporary shedding. PRP uses autologous material but still depends on sterile collection, processing and injection. External biological products add sourcing, contamination, immune and poorly characterised risks.
Seek prompt review for increasing pain, hot spreading redness, pus, fever, marked facial swelling, severe headache, rash or unexpected neurological symptoms. Difficulty breathing, collapse or a severe allergic reaction requires emergency care. Do not treat a suspected infection with leftover medicine.
How should improvement be measured?
Agree on the target before treatment: reduced shedding, standardised hair counts, calibre, photographs or patient-reported coverage. Photographs should use consistent lighting, angle, hair length and styling. Wet versus dry hair or fibres can create dramatic but invalid comparisons.
Define the review interval, expected range, minimum meaningful change and when to stop. Maintenance claims should follow evidence and response, not a lifetime subscription model. Progression of the underlying condition must be separated from the injection’s effect.
Cost and package questions
No PRP or exosome fee was supplied. Cost can include consultation, diagnosis, blood processing system or product, number of sessions, imaging or measurements and follow-up. For an exosome product, traceability and lawful supply are not optional extras; they belong in the basic safety record.
The client-supplied consultation fee is PKR 3,000, subject to confirmation. Ask whether unused sessions are refundable if the diagnosis changes, adverse effects occur or objective response is absent. Do not prepay a long series without clear reassessment points.
Seven questions before any injection
- What is my hair-loss diagnosis and is inflammation active?
- What exact material will be injected and how is it prepared?
- What evidence applies to my diagnosis, not hair loss in general?
- For exosomes, what are the source, manufacturer, batch and local status?
- What known and unknown risks are in the consent?
- How will response be measured, and when will treatment stop?
- What alternatives include medical care, transplant, camouflage or observation?
Patient-first innovation begins with specificity. PRP should not be oversold because it is autologous, and exosome products should not be presumed superior because the science sounds newer.
Practice context supplied by Dr. Saima: Dr. Saima’s website lists PRP for hair restoration. The client has not supplied an exosome product, manufacturer, source, Pakistani regulatory status, preparation protocol, dose, treatment schedule, outcome claim or fee. This article therefore does not state that Dr. Saima currently provides exosome treatment. She must confirm whether any product is offered and document its identity, evidence, sterility and local status before publication or treatment.
Frequently asked questions
Is PRP proven to regrow hair?
Studies and reviews suggest PRP may improve selected hair measures in some patients, but preparation, dosing, follow-up and outcomes vary substantially. It is not a guaranteed cure, and the diagnosis matters. A clinic should state what improvement is realistic and how it will be measured.
Are exosomes approved for hair loss?
Regulatory status is product- and country-specific. The US FDA states that there are no FDA-approved exosome products, but that statement does not determine Pakistani approval. Ask for the exact product and current evidence of Pakistani registration or lawful use rather than relying on the word ‘exosome’.
Are exosomes better than PRP?
Current evidence does not support a universal superiority claim. PRP has more human clinical literature but remains heterogeneous. Exosome research is promising but earlier, with unresolved product standardisation, manufacturing, dose, regulation and long-term-safety issues. Direct high-quality comparisons are limited.
Can either treatment replace a hair transplant?
They do different jobs. Injectables do not move follicles into a bald area. A transplant redistributes finite donor follicles and is also not suitable for every diagnosis. Some patients need medical treatment, observation, camouflage, surgery or a combination after assessment.
What are the risks of scalp injections?
Pain, bleeding, bruising, headache, infection, inflammation and temporary shedding can occur. Autologous PRP avoids an external donor product but still requires sterile processing. Externally produced biological products add sourcing, contamination, immune and unknown long-term risks.
How many sessions will I need?
There is no evidence-based schedule that fits every product, protocol and diagnosis. A series should not be sold before the clinician explains the treatment endpoint, review interval, stop rule, maintenance uncertainty and total cost. Dr. Saima must provide a personal plan.
What should I ask before paying for exosome treatment?
Request product name, manufacturer, cell or material source, processing, batch traceability, sterility testing, storage, Pakistani regulatory status, indication, published human evidence, known and unknown risks, clinician training and the plan for a serious adverse event. If those details are unavailable, marketing claims cannot fill the gap.
Turn an online question into a personal surgical assessment
Bring the onset and pattern of loss, scalp symptoms, family and medical history, pregnancy or postpartum timing, medicines, laboratory results and previous treatments. For PRP, ask how blood is processed and what outcome is measured. For an exosome product, ask for the exact name, manufacturer, source, batch, sterility information, local regulatory status, evidence and adverse-event plan.
Related reading and next steps
- Female hair transplant in Pakistan
- Hair-transplant cost in Pakistan
- Hair-transplant recovery timeline
- PRP hair service
- Hair transplantation service
- Exosome service information
- Book a diagnostic consultation
- About Dr. Saima Waris
- Planning treatment travel to Lahore
Sources and evidence
Medical and regulatory claims were checked against the following professional, government or peer-reviewed sources.
Consultations in Lahore
Two clinic locations, one practice team.
Call or WhatsApp before travelling to confirm the appropriate clinic and current appointment availability.
Medical reviewer
Dr. Saima Waris
MBBS · FCPS (Plastic Surgery) · PMDC 47804-P
Plastic and cosmetic surgeon in Lahore. Articles in this patient-education library are medically reviewed for clinical accuracy, limitations and patient safety.
View Dr. Saima’s profile